HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.

AuthorsPasquale Niscola, Dario Ragusa, Laura Scaramucci, Marco Giovannini, Daniela Piccioni, Andrea Tendas, Alessio Perrotti, Paolo de Fabritiis, Giovanni Del Poeta
JournalAnnals of hematology (Ann Hematol) Vol. 93 Issue 5 Pg. 863-5 (May 2014) ISSN: 1432-0584 [Electronic] Germany
PMID23949377 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • CD55 Antigens
  • CD59 Antigens
  • CD59 protein, human
  • Alemtuzumab
Topics
  • Acute Disease
  • Aged
  • Alemtuzumab
  • Anemia, Hemolytic (chemically induced, immunology, pathology)
  • Antibodies, Monoclonal, Humanized (adverse effects)
  • Antineoplastic Agents (adverse effects)
  • CD55 Antigens (genetics, immunology)
  • CD59 Antigens (genetics, immunology)
  • Coombs Test
  • Down-Regulation
  • Female
  • Gene Expression
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: